References
- Jafri SM, Gordon SC. Epidemiology of Hepatitis C. Clinical Liver
Disease 2018; 12:140-142.
- National Institutes of Health Consensus Development Conference
Statement: management of hepatitis C 2002 (June 10-12, 2002).
Gastroenterology 2002; 123(6):2082-2099.
- Polaris Observatory HCV Collaborators. Global prevalence and genotype
distribution of hepatitis C virus infection in 2015: A modelling
study. Lancet Gastroenterol Hepatol 2017; 2:161-176.
- Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of
hepatitis C virus infection: New estimates of age-specific antibody to
HCV seroprevalence. Hepatology 2013; 57:1333-42.
- Bian DD, Zhou HY, Liu S, et al. Current treatment status and barriers
for patients with chronic HCV infection in mainland China: a national
multicenter cross-sectional survey in 56 hospitals. Medicine 2017;
96(34):e7885.
- Chinese Society of Hepatology and Chinese Society of Infectious
Diseases. The guideline of prevention and treatment for hepatitis C:
2015 updated version. Clin J Viral Dis 2015; 5(6):425-447.
- Zhao N, Xie R, Zhao X, et al. Safety, Tolerability and
Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral
Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.
Clin
Drug Investig. 2019; 39(7):671-681.
- Zhang H, Zhu X, Li Q, et al. Clinical evaluation of efficacy,
tolerability and pharmacokinetics of yimitasvir phosphate in patients
infected with hepatitis C virus. J Pharm Pharmacol 2018;
70(7):855-864.
- Brieva
T,
Rivero
A,
Rivero-Juarez
A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for
the treatment of hepatitis C virus infection. Expert Opin Drug Metab
Toxicol 2017; 13(4):483-490.
- German
P,
Mathias
A,
Brainard
D, et al. Clinical Pharmacokinetics and Pharmacodynamics of
Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the
Treatment of Hepatitis C.
Clin
Pharmacokinet 2016; 55(11):1337-1351.
- Beal
SL.
Ways to fit a PK model with some data below the quantification limit.
J Pharmacokinet Pharmacodyn 2001; 28(5):481-504.
- Cockcroft DW, Gault MH. Prediction of Creatinine Clearance from Serum
Creatinine. Nephron 1976; 16:31-41.
- Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes
estimates for diagnostics: problems and solutions. AAPS J 2009;
11(3):558-569.
- Carver PL, Fleisher D, Zhou SY, et al. Meal composition effects on the
oral bioavailability of indinavir in HIV-infected patients. Pharm Res
1999; 16(5):718-724.
Figure 1. The chemical structure of yimitasvir.
Figure 2. Goodness-of-fit plots of final population
pharmacokinetics model. (A) Observed drug concentration (DV) versus
individual prediction (IPRED); (B) DV versus population prediction
(PRED); (C) conditional weighted residual (CWRES) versus PRED; (D) CWRES
versus time after dose (TAD). The black line is the line of unity or the
zero reference line, and the red line is the result of locally weighted
scatterplot smoothing (loess).
Figure 3. Prediction-corrected visual predictive check (pcVPC)
plot stratified by study. Black circles are observed yimitasvir
concentrations, red solid lines represent the median of predicted
concentrations, and grey dashed lines represent the 5th and 95th
percentiles of predicted concentrations.
Figure 4. Sensitive plot comparing the effect of covariates on
yimitasvir steady state exposure. (A) AUCss; (B)
Ctrough,ss; (C) Cmax,ss. A typical
subject is a healthy male volunteer with ALT value of 31.6 IU
l-1 taking yimitasvir under fasted state more than 10
h. The black bar represents the 5th to 95th percentile of the exposure
calculated using empirical Bayes estimates of the population after
administration of yimitasvir 100 mg once daily for 12 consecutive weeks.
Continuous covariates were evaluated at the 5th to 95th percentile of
the population.